Business

Shareholders in Germany sue Bayer over glyphosate weedkiller

Claims for damages, were filed at a regional court in Cologne, almost six months ago 

Updated 5 years ago · Published on 24 Jan 2021 3:55PM

Shareholders in Germany sue Bayer over glyphosate weedkiller
Bayer acquired Roundup when it took over the US agrochemical company Monsanto in a US$60 billion deal in 2018. –Twitter pic, January 24, 2021

BERLIN –  Investors have taken legal action in Germany against the chemical giant Bayer, accusing it of not having informed them of the risks associated with its glyphosate weedkiller, their lawyers said on Friday.

“We have filed suit against Bayer,” said the law firm Tilp, which represents several investors.

German business weekly Wirtschaftswoche first reported the litigation.

The claims for damages, which were filed at a regional court in Cologne “almost six months ago” had not been made public until now. 

The shareholders allege that Bayer did not inform them sufficiently about the legal and economic risks associated with the glyphosate weedkiller Roundup, an accusation the company denies.

“We consider the suits to be unfounded and will defend ourselves accordingly,” Bayer said in a statement.

Bayer acquired Roundup when it took over the US agrochemical company Monsanto in a US$60 billion (RM242.58 billion) deal in 2018. 

The World Health Organization’s cancer branch labelled Roundup a “probable carcinogen” in 2015, a claim Bayer strongly disputes. 

Bayer has since paid billions in damages in the US amid thousands of court cases that allege Roundup causes cancer.

The Leverkusen-based company put an end to a large number of the  suits in the US in June last year with a US$11 billion settlement. 

But the final amount is still to be decided after a California judge questioned the agreement.

Bayer’s share price has lost around half its value since it acquired Monsanto. 

The total number of claimants has not been specified by Tilp, but it said that they “are not many at the moment”.

But the case "interests several hundred small shareholders" and institutional investors, says Tilp.

The law firm estimates that it could eventually claim "more than a billion euros in damages" from Bayer. 

Another law firm, Hausfeld, is suing Bayer for €37 million (RM182.12 million) on behalf of US investor Kingstown Capital Management, Wirtschaftswoche reported. – AFP, January 24, 2021

Related News

Malaysia / 1d

MP to raise commingled oil cargo tax uncertainty in Parliament

Business / 1d

Independent review needed, not blind denial, to address US claims – maritime expert

World / 2d

Iran’s two-pronged strategy: The eradication of US forces in the Gulf and political defeat in Washington

Opinion / 1w

Wikipedia has become compromised by intelligence agencies and ideological capture

Opinion / 2w

Is the South China Sea moving from a ‘zone of peace’ towards the next conflict area?

Malaysia / 4w

Malaysia must prepare for the effects of the Gulf War

Spotlight

Malaysia

RM245m Penang Hill cable car project 32 per cent complete - CM

By Ian McIntyre

Malaysia

Six locals charged over alleged kidnapping of Singaporean couple in Johor

Malaysia

PM: No political, racial or religious shield for those found guilty in TH, Felda probes

Malaysia

Singapore security guard jailed 14 days, fined RM7,000 for insulting Islam

Health

Dengue cases soar 56% to 58,079 as nation records 55 deaths

Malaysia

NGOs urge BERSAMA to put Indian community agenda on political radar

By Alfian Z.M. Tahir

Health

MOH warns seniors against unproven hydrogen inhalers

Malaysia

Former Tabung Haji CEO remanded seven days as MACC RCI probe deepens

Malaysia

21 held in KLIA-Nilai crackdown on alleged online love scam syndicate

You may be interested

Business

Tey Por Yee and four others ordered to pay RM103.75m in SC civil suit

Business

Robo.ai expects shareholders’ equity to turn positive after restructuring

By Alfian Z.M. Tahir

Business

Oil prices surge as US-Iran standoff, Ukraine strikes rattle global energy markets

Business

Independent review needed, not blind denial, to address US claims – maritime expert